Health Ad Compliance on Native Networks: What Gets Approved vs Banned

Native networks approve health ads that stay at symptom level, promise no specific outcomes, use real brands and honest imagery — and reject or later ban ads built on cure claims, disease-treatment promises, before/after photos, fabricated authority and manufactured urgency. That's the written rule. The live picture is messier: OpenAdLibrary's index holds 24,472 live health creatives across 49 networks (July 2026), and it contains both squeaky-clean brand campaigns running five-plus weeks and "Cardiologist says" advertorials that would fail any written policy — because native ad enforcement is a pipeline with gaps, not a wall. This guide maps what gets banned, what sails through, where the gray zone actually sits, and how to build health campaigns that survive review, re-review and regulator attention.

Compliance is three layers, not one#

Health advertisers who only think about the network's approval queue get blindsided. There are three enforcement layers, each with different timing and different penalties:

1. Network creative review. Every serious native network human- or machine-reviews health creatives and landing pages before serving. This layer rejects; it rarely punishes. Policies differ by network and change often — treat the network's current documentation as the source of truth, not last year's forum thread.
2. Post-approval enforcement. Approval is not immunity. Networks re-sweep running campaigns, act on publisher and user complaints, and ban accounts retroactively. The ad that "got through" can still take your account, your pixel data and your balance with it a month later.
3. Regulators. In the US, the FTC requires that health claims be backed by competent and reliable scientific evidence — its Health Products Compliance Guidance is unusually explicit — and FTC actions name advertisers, not networks. Disclosure duties on advertorial funnels come on top; see our summary of the FTC's advertorial disclosure rules.

The rest of this guide works within that stack: what layer one rejects, what layer two takes down, and what layer three makes expensive.

What gets rejected or banned#

The recurring kill-list across native networks, from most to least universally enforced:

• Cure and treatment claims for supplements. "Cures," "treats," "prevents," "reverses" attached to a disease name is the brightest line in health advertising. Supplements making disease claims violate both network policy and FTC/FDA rules — this is the category that produces account bans, not just rejections.
• Specific measurable outcomes with timeframes. "Lose 20 lbs in 30 days," "restores hearing in two weeks." Quantified promises require substantiation nobody selling through an advertorial has.
• Before/after body imagery. Most networks prohibit or heavily restrict transformation photos — weight loss, skin, dental — both in the creative and on the lander.
• Fabricated authority and endorsements. Fake doctor personas, invented "as seen on" logos, celebrity images the advertiser has no rights to. This is also the fastest route to a trademark or right-of-publicity complaint.
• Fear-based and graphic imagery. Close-ups of skin conditions, surgical imagery, distressing symptom photography — rejected on user-experience grounds even when the claim behind them is defensible.
• "Banned soon" and scarcity theater. Headlines like "Will This Supplement Be Banned?" manufacture urgency from nothing. Some networks let them through; the pattern is a reliable marker of campaigns that die in layer two.
• News and government impersonation. Advertorials styled as breaking news or official health-agency notices. Beyond network policy, this is the pattern regulators cite most in enforcement actions.

What gets approved — and keeps running#

The approved end of the spectrum is visible in the index's longevity data. The longest-running health and hearing creatives we capture share a structure:

• Symptom-level questions instead of outcome claims. "Struggling to Hear Clearly? Discover a Device Transforming Lives" (Audika, Taboola) had run 37 consecutive days at capture. It names a symptom the reader self-identifies with and promises discovery, not results.
• Real brands with verifiable credentials. "Discover comfortable and discreet hearing solutions at Boots" (Boots Hearingcare) — 38 days live. A recognizable retailer, a soft claim, a landing page that matches.
• Education-first advertorials. Mechanism stories ("why standard advice misses X") that inform before selling, carry visible sponsored-content disclosure, and route to an offer page that repeats no banned claim.
• Price and comparison angles. "How much do hearing aids cost" style framing converts on curiosity about a real purchase decision — no medical claim required.

The pattern is not an accident of taste: these structures survive because every layer of the stack can re-review them without finding a violation. Long ad longevity in health is close to a compliance certificate — nobody runs a creative for five weeks that review keeps killing.

What a fully compliant health funnel looks like end to end: the ad asks a symptom question over honest product photography; the pre-lander is a disclosed, education-first advertorial explaining the mechanism — why hearing loss creeps, what modern devices actually do — with one call to action; the offer page carries the brand, the price or consultation booking, real contact details and a refund policy; and every claim on all three pages is one the advertiser could hand evidence for tomorrow. Nothing in that structure sacrifices conversion. The advertorial still sells; it just sells with material that survives scrutiny — which is precisely why the advertisers running this structure are the ones still live after five weeks.

The gray zone the live index reveals#

Search the index for health ads and you'll find creatives that plainly stretch the written rules, live on major networks:

• "Cardiologist: 2 Veggies Will Kill Your Belly Fat Overnight! (Try It)" — captured on Outbrain, 22 days running.
• "Doctors Call It 'Nature's Morphine' — Pain Relief Without A Prescription" — MGID, 16 days.
• "Endocrinologist: If You Have Diabetes, Read This Before It's Removed!" — Revcontent, captured at 1–3 days old across multiple variants.

Why does this exist if the policies ban it? Review capacity versus creative volume: aggressive advertisers submit variants faster than queues re-check them, resubmit rejected creatives with cosmetic edits, and treat account bans as a cost line. Mid-tier networks with thinner review teams and more revenue pressure tolerate more; per-geo enforcement is uneven; and the advertorial's landing page — where the worst claims live — changes after approval more often than networks re-crawl. Our guide to ad spy research on MGID and Revcontent shows how visible this economy is once you look.

Knowing the gray zone exists is useful intelligence. Building your business in it is a different decision, and the index data argues against it: the claim-heavy cohort skews days old while compliant brand angles run for weeks, ban waves wipe out accounts along with their pixel data and optimization history, publishers blacklist repeat-offender advertisers, and FTC enforcement lands on the advertiser of record. Churn economics can be made to work — some shops do — but it is a treadmill, not an asset.

When you study a health competitor, three signals reveal which strategy they're running:

1. Longevity distribution. An advertiser whose creatives cluster at 20+ days is running compliant economics; one whose entire inventory is under a week old is churning — and copying their angles imports their ban risk along with their hooks.
2. Network tier. Angles that exist only on mid-tier networks usually can't pass premium review. If a competitor runs the same funnel on Taboola and MGID simultaneously, the funnel is clean; if their Taboola presence uses visibly softer claims than their MGID presence, you're looking at a two-tier compliance strategy.
3. Lander-to-ad claim gap. Trace the click. A soft ad over a hard lander is a campaign living on borrowed review time.

Network-by-network reality#

Written policies converge; enforcement postures differ. A qualitative map — verify against each network's current documentation before building:

Two practical corollaries. First, an angle rejected on Taboola may be approved on MGID — but the migration itself is information: you're now in the churn economy, price it that way. Second, watch what long-running advertisers in your niche get away with per network rather than reasoning from policy PDFs — a native ad spy tool filtered to your sub-vertical, sorted by longevity, is the most current enforcement map that exists. This is where OpenAdLibrary earns its keep for health buyers: the index shows you, per network, which health angles are surviving review right now.

Sub-categories with extra rules#

Several health sub-categories carry restrictions beyond the general policy, and the specifics change often enough that the only safe instruction is: check the network's current documentation for your exact category before building. The recurring extras, qualitatively: hearing and medical devices may require certification or category approval on premium networks; weight loss carries the tightest claim and imagery restrictions of any sub-vertical; CBD and cannabis-adjacent products range from geo-restricted to fully prohibited; anything positioning itself against prescription medication ("without a prescription") sits in the highest-risk tier everywhere; and personal-health conditions can trigger targeting restrictions on top of creative rules. Category rules are also where networks differ most from each other — which is exactly why the per-network live index beats any generalized guide, including this one.

Your landing page fails review more often than your ad#

Most health rejections practitioners complain about are not the creative — they're the click path. Networks review the full funnel: the pre-lander, the offer page, and the consistency between all three. The recurring failure points:

• Claim escalation. A compliant ad clicking through to a lander shouting cure claims fails as a unit. The strictest claim anywhere in the funnel is what you're judged on.
• Missing advertorial disclosure. Story-style landers must be identifiable as advertising — clear sponsored-content labeling, an identifiable advertiser, working contact and policy pages. The anatomy of compliant examples is in our advertorial landing page teardown.
• Fake trust furniture. Invented review counts, fabricated "doctor recommended" badges, logo walls of outlets that never covered the product.
• Headline mismatch. The lander must deliver what the ad promised. Eligibility ads that open to an unrelated supplement pitch are an instant rejection and an account-trust hit.

Build the lander to the same standard as the creative and health approval rates change dramatically — this, more than headline wording, is what separates buyers who "always get approved" from those who don't.

Never cloak#

The tempting shortcut — showing reviewers a clean page while sending traffic to the real one — is terminal. Cloaking violates every network's terms, converts a policy problem into a fraud problem, and is increasingly detectable from outside: independent transparency indexes capture ads and their true landing pages continuously, which means the evidence of what actually ran outlives the campaign — as our breakdown of how cloaked funnels get exposed explains in detail. Networks that catch cloaking don't reject the creative; they ban the account, and in health, regulators treat cloaking as evidence of intent.

The pre-submission checklist#

Approval problems are cheapest to fix before submission — every rejection slows the account, and every resubmission gets reviewed with more suspicion than the last. Health buyers who maintain high first-pass approval rates treat the checklist below as part of funnel construction, not a final gate: the copywriter works from it, the designer works from it, and the campaign that reaches the review queue has already passed a stricter reviewer in-house. Run every health campaign through this before submitting:

1. No disease name attached to "cures," "treats," "prevents" or "reverses" — anywhere in the funnel.
2. No quantified outcome plus timeframe.
3. No before/after body imagery in creative or lander.
4. Every authority figure real, named and rights-cleared; every testimonial genuine and typical, with disclosure where required.
5. Sponsored-content disclosure visible on the advertorial without scrolling.
6. Advertiser identity, contact and refund policy present on the lander.
7. Ad headline, pre-lander premise and offer page all tell the same story.
8. Claims backed by evidence you actually possess — the FTC standard is competent and reliable scientific evidence, and it applies whether or not any network asks.
9. Substantiation, licensing and geo-restrictions checked against the network's current documentation for your specific health sub-category.
10. A pass through the live index for your niche: study what has run 30+ days on your target network — that cohort is the de facto definition of "approved" — and, if a competitor is succeeding with something you can't get approved, assume churn economics or a gray zone that closes, not a loophole you missed.

Health is the biggest vertical in native advertising precisely because these rules can be satisfied while still converting cold traffic. The advertisers who last treat compliance as funnel architecture, not censorship — and the 37-day hearing-aid ads quietly outearning the banned-soon supplements are the proof.